Suscriptores   Asóciese  
Textos Completos Autorizados
LA CABERGOLINA EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON

v-estudie-lo-mejor.gif
Expertos Invitados





LA CABERGOLINA EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON

(especial para SIIC © Derechos reservados)
La cabergolina es una opción adecuada para los pacientes con enfermedad de Parkinson de novo.
pastormu9.jpg Autor:
Pau Pastor Munoz
Columnista Experto de SIIC

Institución:
Department of Psychiatry and Genetics Washington University School of Medicine

Artículos publicados por Pau Pastor Munoz
Coautor
Eduardo Tolosa* 
Unidad de Parkinson y Movimientos Anormales. Servicio de Neurología, Institut Clínic de Malalties del Sistema Nerviós, IDIBAPS. Hospital Clínic, Facultad de Medicina de la Universidad de Barcelona, Ba*
Recepción del artículo
11 de Enero, 2005 		Aprobación
22 de Febrero, 2005
Primera edición
13 de Septiembre, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

LA CABERGOLINA EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON

Resumen
La cabergolina (1-[(6-alelilergolin-8 beta-il)carbonil]-1-[3-(dimetilamino)propil]-3-etilurea) es un novedoso agonista de los receptores dopaminérgicos D2 para la terapia farmacológica en la enfermedad de Parkinson (EP). La cabergolina tiene una vida media larga (alrededor de 68 horas) lo que permite su administración en dosis única diaria. En base a la información disponible en monoterapia, la cabergolina induce una mejoría de los síntomas similar al proporcionado por otros agonistas dopaminérgicos. En pacientes con EP de novo, la cabergolina en monoterapia representa una opción adecuada para el tratamiento sintomático ya que mejora los síntomas motores, retrasa la aparición de complicaciones motoras por levoterapia y disminuye los requerimientos de levodopa. Como tratamiento coadyuvante a la levodopa es un fármaco apropiado debido a que mejora la función motora, reduce la intensidad y duración de los periodos off y reduce los requerimientos de levodopa. Estudios preliminares sugieren que la cabergolina es eficaz en el tratamiento de la acinesia y la distonía nocturna en la EP avanzada. La cabergolina es bien tolerada. Los efectos colaterales se producen principalmente a nivel del sistema nervioso central y del aparato digestivo. La eficacia de la cabergolina con respecto a otros agonistas dopaminérgicos en el control de los síntomas de la EP debe ser analizada en futuros estudios.

Palabras clave
Cabergolina, enfermedad de Parkinson, agonistas dopaminérgicos


Artículo completo
(castellano)
Extensión:  +/-6.81 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

CABERGOLINE USED IN THE TREATMENT OF PARKINSON’S DISEASE

Abstract
Cabergoline (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is a new agonist of the D2 dopaminergic receptors used in the treatment of Parkinson’s disease. Cabergoline is characterized by unique pharmacologic properties, such as its long plasma half-life (about 68 hours), which allows for once a day administration. Cabergoline is well tolerated, as has been shown in several clinical trials. Based on the information available, we suggest that cabergoline produces an improvement in the symptoms of Parkinson disease similar to those produced by other dopaminergic agonists. Cabergoline monotherapy, when used in previously untreated patients, is an appropriate option for the symptomatic treatment of Parkinson disease. Cabergoline improves motor symptoms, delays the presentation of levodopa-induced motor complications, and diminishes the amount of levodopa required for the control of the symptoms. We suggest that cabergoline is an adequate adjuvant treatment for Parkinson disease. There is improvement in motor symptoms (without substantially increased dyskinesias), reduced severity and duration of the wearing-off period, and diminished need for levodopa. Cabergoline can also be useful in the treatment of sleep disturbances associated with advanced Parkinson disease such as nocturnal akynesia and dystonia. However, additional studies on cabergoline’s effects in nocturnal disturbances associated with Parkinson disease are still required. Cabergoline is a well tolerated drug. Its side effects are seen mainly in the digestive and nervous system (central and peripheral). The efficacy of cabergoline in comparison to other dopaminergic agonists should be tested in future clinical studies.

Key words
Cabergoline, Parkinson disease, dopaminergic agonists

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 6.81 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Stocchi F. Dopamine agonists in Parkinson’s disease: what is their role in early treatment CNS Drugs 1998;10:159-170.
  2. Cocchiara G, Benedetti MS. Excretion balance and urinary metabolic pattern of [3H]cabergoline in man. Drug Metabol Drug Interact 1992;10(3):199-211.
  3. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997;48(2):363-8.
  4. Benedetti MS, Dostert P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990;187(3):399-408.
  5. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson’s disease. Drugs 1998;55 Suppl 1:10-6.
  6. Grondin R, Goulet M, Di Paolo T, Bedard PJ. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 1996;735(2):298-306.
  7. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli MG, Cocchiara G, Dostert P. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica 1993;23(12):1377-89.
  8. Fahn S, Elton RL, Committee MotUD. Unified Parkinson’s disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease. Vol 2. Florham Park (NJ). MacMillan Healthcare information 1987:153-163.
  9. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson’s disease. Drugs 2004;64(18):2125-41.
  10. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243(1):68-72.
  11. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson’s disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19(3):202-12.
  12. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology 1996;47(3):785-8.
  13. Ulm G, Schüler P, MODAC study group. Cabergoline versus pergolide: a video-blinded, randomized, multicenter crossover study. Aktuel Neurol 1999;25:360-365.
  14. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 1996;46(4):1062-5.
  15. Musch B, Bonura L. Cabergoline once a day as adjuntive therapy to levodopa in Parkinson’s disease [abstract no.3]. Movement Disorders 2000;15(Suppl. 3):121.
  16. Destee A, Schneider E, Gershanik O, Dom R, Tichy J, Korczyn AD. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications. (not on treatment with DA-agents). Mov Dis 1996;11 suppl 1:269.
  17. Yanagisawa N, Kowa H, Mizuno Y, et al. The clinical evaluation of GC-101 (cabergoline) in Parkinson’s disease with combined use of L-DOPA: a multi-center duoble-blind comparative study vs. bromocriptine mesylate. Rinsho Iyaku 1996;12(17):3757-3798.
  18. Schneider E, Gershanik O, Dom R, et al. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications (on treatment with DA-agents) [abstract no. SS27]. Movement Disorders 1996;11(Suppl 1):29.
  19. Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2003;3.
  20. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55 Suppl 1:23-30.
  21. Rinne UK, and the PKDS009 Collaborative Study Group. A five-year, double-blind study with cabergolina versus levodopa. Parkinsonism and Related Disorders 1999;5 (suppl):74.
  22. Chaudhuri KR, Bhattacharya K, Agapito C, Porter MC, Mills J, Clough C. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: A parallel study with controlled release levodopa. Eur J Neurol 1999;6(suppl 5):S11-S15.
  23. Chaudhuri KR, Agapito C, Porter MC, et al. Cabergoline, along-acting dopamine agonist, overcomes levodopa refractory nocturnal disabilities in Parkinson’s disease. Neurology 1999;52(Suppl. 2):263.
  24. Ghatani T, Agapito C, Bhattacharya KF, et al. Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal "off" periods causing sleep disruption in Parkinson’s disease. European Journal of Neurology 2001;8(Suppl. 1):8-11.
  25. Hogl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology 2003;28(10):1866-70.
  26. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18(11):733-46.
  27. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson’s disease: long-term follow-up. Neurology 1993;43(12):2587-90.
  28. Jori MC, Franceschi M, Giusti MC, Canal N, Piolti R, Frattola L, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson’s disease. Adv Neurol 1990;53:539-43.
  29. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43(3 Pt 1):613-6.
  30. Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’s disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43(10):1981-4.
  31. Appiah-Kubi L, Nisbet A, Burn DJ, Ray CK. Cabergoline monotherapy in clinical practice: A two year observational study of tolerability and efficacy in young, old and very elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;73:231.
  32. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs 1998;55 Suppl 1:17-22.
  33. Forbes A, Brechany U, Stegie F. Use and tolerability of cabergoline in young and older people with Parkinson’s disease: a multi-center observational study. J Appl Res 2003;3(4):356-362.
  34. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson’s disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001;108(1):71-7.
  35. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18(6):659-67.
  36. Pharmacia. Cabser tablets 1 mg [UK prescribing information]. Pharmacia: Milton Keynes 2003.
  37. Del Dotto P, Gambaccini G, Caneparo D, Berti C, Bernardini S, Bonuccelli U. Bedtime cabergoline in Parkinson’s disease patients with excessive daytime sleepiness induced by dopamine agonists. Neurol Sci 2003;24(3):170-1.
  38. Ferreira JJ, Pona N, Costa J, et al. Somnolence as an adverse drug reaction od antiparkinsonian drugs: a meta-analysis of published randomised placebo-controlled trials [abstrac no. P659]. Movement Disorders 2000;15(Suppl. 3):128.
  39. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30(4):613-6.
  40. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5(2):263-5.
  41. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999;74(4):371-5.
  42. Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson’s disease. Heart 2004;90(8):e47.
  43. Muller T, Fritze J. Fibrosis Associated With Dopamine Agonist Therapy in Parkinson’s Disease. Clinical Neuropharmacology 2003;26(3):109-111.
  44. DA agonists – Ergot derivatives: Cabergoline: Management of Parkinson's disease. Mov Disord 2002;17 Suppl 4:S68-71.
  45. Agency MC. Committee on Safety of Medicines. Current Problems in Pharmacovigilance 2002;28.
  46. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson’s disease. Eur Neurol 2001;46 Suppl 1:18-23.
  47. Porter MC, Appiah-Kubf LS, Chaudhuri KR. Treatment of Parkinson’s disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int J Clin Pract 2002;56(6):468-74.
  48. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines.American Academy of Neurology. Neurology 1998;50(3 Suppl 3):S1-57.
  49. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1981;44(11):1020-3.
  50. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002;58(4 Suppl 1):S42-50.
  51. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58(1):11-7.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517